<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474899</url>
  </required_header>
  <id_info>
    <org_study_id>RA-4-1-7565</org_study_id>
    <nct_id>NCT04474899</nct_id>
  </id_info>
  <brief_title>Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension</brief_title>
  <acronym>OHT</acronym>
  <official_title>Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Perth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Perth Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether sympathoinhibition with moxonidine could
      provide added metabolic benefit compared to the second line therapy in the current
      guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, cross-over study. Participants will be randomly assigned
      to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the
      alternate treatment.

      Comprehensive testing will occur after each 12 week treatment phase and will include
      assessment of muscle sympathetic nerve activity, gut microbiome analysis and metabolic
      markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2015</start_date>
  <completion_date type="Anticipated">June 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double blind cross over study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>30 weeks</time_frame>
    <description>Both Systolic and diastolic blood pressure assessed by office and ambulatory blood pressure monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood glucose levels</measure>
    <time_frame>30 weeks</time_frame>
    <description>Changes in glycemic control through oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota profile</measure>
    <time_frame>30 weeks</time_frame>
    <description>Change in gut microbiota assessed by short chain fatty acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels in blood</measure>
    <time_frame>30 weeks</time_frame>
    <description>change in triglyceride, HDL and LDL levels in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxonidine 0.4mg/daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine 0.4 MG</intervention_name>
    <description>Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 25 -65 years

          -  (Body Mass Index) BMI≥30kg/m2

          -  Currently weight stable (+/- 3% in previous 6-12 months and not on any specific
             exercise or dietary program)

          -  Elevated clinic systolic (Blood Pressure) BP ≥135 or diastolic BP ≥85mmHg,

          -  on ACE inhibitor for at least 6 weeks prior to baseline assessment

        Exclusion Criteria:

          -  Grade 2-3 hypertension (systolic office BP &gt;160, diastolic office BP &gt;100 mmHg)

          -  Secondary causes of hypertension

          -  CKD (Chronic kidney disease) stage 4-5 {(estimated glomerular filtration)
             eGFR&lt;30ml/min}

          -  Heart failure NYHA (New York Heart Association) class II-IV

          -  Recent CV (cardiovascular) event (acute myocardial infarction, acute coronary
             syndrome, stroke or transient ischaemic attack within the previous six months)
             unstable psychiatric condition

          -  medication such as corticosteroids, several antidepressants and antipsychotics

          -  Female participants of childbearing potential must have a negative pregnancy test
             prior to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Australia and Royal Perth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revathy Carnagarin, MD</last_name>
    <phone>+61 8 92240316</phone>
    <email>revathy.carnagarin@uwa.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anu Joyson, MSN</last_name>
    <phone>+61 8 92240390</phone>
    <email>anu.joyson@uwa.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dobney Hypertension Centre</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6155</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schlaich</last_name>
      <phone>+61 8 92240390</phone>
      <email>markus.schlaich@uwa.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Revathy Carnagarin</last_name>
      <phone>+61 8 92240316</phone>
      <email>revathy.carnagarin@uwa.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Schlaich</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Revathy Carnagarin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Carnagarin R, Gregory C, Azzam O, Hillis GS, Schultz C, Watts GF, Bell D, Matthews V, Schlaich MP. The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. Curr Hypertens Rep. 2017 Oct 28;19(12):99. doi: 10.1007/s11906-017-0795-1. Review.</citation>
    <PMID>29080925</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Perth Hospital</investigator_affiliation>
    <investigator_full_name>Dr Markus Schlaich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared to maintain anonymity and confidentiality of the participants</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

